Financiado en parte por Amgen, Eli Lilly and Company, AstraZeneca, Sanofi, PepsiCo, Dairy Farmers of Canada, Alberta Pulse Growers Commission, Novo Nordisk, Servier, International Nut and Dried Fruit Council, International Sweeteners Association
Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials
Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, Li D, Sievenpiper J, Duvnjak L, Vuksan V
The American journal of clinical nutrition · 48 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Amgen
- Empresa
- Eli Lilly and Company
- Empresa
- AstraZeneca
- Empresa
- Sanofi
- Empresa
- PepsiCo
- Grupo de la industria
- Dairy Farmers of Canada
- Organización sin fines de lucro
- Canadian Cardiovascular Society
- Organización sin fines de lucro
- Diabetes Canada
- Organización sin fines de lucro
- Canadian Nutrition Society
- Grupo de la industria
- Alberta Pulse Growers Commission
- Organización sin fines de lucro
- Physicians' Services Incorporated Foundation
- Universidad u hospital
- University of Toronto
- Empresa
- Novo Nordisk
- Organización sin fines de lucro
- European Association for the Study of Diabetes
- Empresa
- Servier
- Grupo de la industria
- International Nut and Dried Fruit Council
- Grupo de la industria
- International Sweeteners Association
- Gobierno
- Canadian Institutes of Health Research
- Universidad u hospital
- Banting and Best Diabetes Centre, University of Toronto
Según 19 financiadores declarados.
Publicación
- Publicado
- 2018-09-06 · Am J Clin Nutr · vol. 108 · número 5 · págs. 922–932
- Editorial
- Elsevier BV
- Citado
- 97 citas · más que el 72% de estudios similares · 1.3× el promedio de su campo
- Referencias
- 53 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Food composition and properties · Lipoproteins and Cardiovascular Health · Natural Products and Biological Research
- Palabras clave
- psyllium, Plantago ovata, LDL cholesterol, non-HDL cholesterol, apolipoprotein B, hypercholesterolemia, serum lipids, cardiovascular risk, atherosclerosis, dietary fiber supplementation, hypolipidemic effect, quality of evidence grading, GRADE, risk of bias assessment
- MeSH
- humans, plantago, hypercholesterolemia, cholesterol, apolipoproteins b, psyllium, dietary fiber, adult, middle aged, female, male, cholesterol, ldl, cholesterol, hdl
10 autores
- Elena Jovanovski
- Shahen Yashpal
- Allison Komishon
- Andreea Zurbau
- Sonia Blanco Mejía
- Hoang Vi Thanh Ho
- Dandan Li
- John L. Sievenpiper
- Lea Smircic Duvnjak🇭🇷University of Zagreb; Klinička bolnica Merkur
- Vladimir V.V. Vuksan🇨🇦 · autor de correspondenciaSt. Michael's Hospital; University of Toronto
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Studies have identified viscous dietary fiber as potentially attenuating cholesterol, including psyllium, which reduces LDL cholesterol and thus may complement cardiovascular disease (CVD) treatment.
Objectives
The aims of this study were to update evidence on the effect of psyllium on LDL cholesterol and to provide an assessment of its impact on alternate markers: non-HDL cholesterol and apolipoprotein B (apoB).
Design
Medline, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials were searched through 3 October 2017. Independent reviewers extracted relevant data and assessed risk of bias. We included randomized controlled trials with a duration of ≥3 wk that assessed the effect of psyllium on blood lipids in individuals with or without hypercholesterolemia. Data were pooled by using the generic inverse variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by Cochran's Q statistic and quantified by the I2 statistic. Overall quality of the evidence was assessed by using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.
Results
We included 28 trials in our analysis (n = 1924). Supplementation of a median dose of ∼10.2 g psyllium significantly reduced LDL cholesterol (MD = -0.33 mmol/L; 95% CI: -0.38, -0.27 mmol/L; P < 0.00001), non-HDL cholesterol (MD = -0.39 mmol/L; 95% CI: -0.50, -0.27 mmol/L; P < 0.00001), and apoB (MD = -0.05 g/L; 95% CI: -0.08, -0.03 g/L; P < 0.0001). Effect estimates for LDL cholesterol and non-HDL cholesterol were graded as moderate quality on the basis of downgrades for inconsistency and graded as high quality for apoB.
Conclusion
Psyllium fiber effectively improves conventional and alternative lipids markers, potentially delaying the process of atherosclerosis-associated CVD risk in those with or without hypercholesterolemia. This trial is registered at www.clinicaltrials.gov as NCT03346733.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.